Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis

Details for Australian Patent Application No. 2007299726 (hide)

Owner BrainCells, Inc.

Inventors Morse, Andrew; Redwine, Jeff; Hoffmaster, Christine; Barlow, Carrolee; Treuner, Kai; Lorrain, Kym I.; Carter, Todd A.

Agent Spruson & Ferguson

Pub. Number AU-A-2007299726

PCT Pub. Number WO2008/036846

Priority 60/826,710 22.09.06 US

Filing date 20 September 2007

Wipo publication date 27 March 2008

International Classifications

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 31/135 (2006.01) - having aromatic rings, e.g. methadone

A61K 31/138 (2006.01) - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine

A61K 31/22 (2006.01)

A61K 31/343 (2006.01) - condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone

A61K 31/365 (2006.01) - Lactones

A61K 31/366 (2006.01) - having six-membered rings, e.g. delta-lactones

A61K 31/381 (2006.01) - having five-membered rings

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 31/4015 (2006.01) - having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

A61K 31/404 (2006.01)

A61K 31/4196 (2006.01) - 1,2,4-Triazoles

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/4525 (2006.01)

A61K 31/505 (2006.01) - Pyrimidines

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

Event Publications

23 April 2009 PCT application entered the National Phase

  PCT publication WO2008/036846 Priority application(s): WO2008/036846

7 May 2009 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the name BrainCells, Inc., Application No. 2007299726, under INID (54) correct the title to read Combination comprising an HMG-CoA reductase inhibitor and a second neurogenic agent for treating a nervous system disCorrigenda order and increasing neurogenesis.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007299727-Self preserved aqueous pharmaceutical compositions

2007299723-Nitrogen containing substituted heterocycles as platelet ADP receptor inhibitors